

1 **Title: Utilization of CoRDS Registry to Monitor Quality of Life in Patients with VCP**  
2 **Multisystem Proteinopathy**

3  
4 Eiman Abdoalsadig<sup>1,2\*</sup>, Merwa Hamid<sup>1\*</sup>, Allison Peck<sup>3\*</sup>, Leepakshi Johar<sup>1,4</sup>, Virginia Kimonis<sup>1,5,6</sup>

5 \* Contributed equally to the work and should be considered co-first authors

6 **Affiliations:**

7 <sup>1</sup>Division of Genetics and Genomic Medicine, Department of Pediatrics, University of California  
8 Irvine Medical Center, CA, USA

9 <sup>2</sup>Yale School of Public Health, CT, USA

10 <sup>3</sup>Cure VCP Disease, Inc., Warner Robins, Georgia

11 <sup>4</sup>College of Osteopathic Medicine of the Pacific, Western University of Health Sciences, Pomona,  
12 CA, USA

13 <sup>5</sup>Department of Neurology, University of California Irvine Medical Center, CA, USA

14 <sup>6</sup>Department of Pathology, University of California Irvine Medical Center, CA, USA

15 **Correspondence:**

16 Virginia Kimonis, MD. MRCP

17 Professor, Department of Pediatrics

18 Division of Genetics and Genomic Medicine

19 University of California-Irvine

20 Lab and FEDEX: Hewitt Hall, Rm 2038,

21 Health Sciences Rd., Irvine CA 92697

22 Tel: (949) 824-0571

23 [vkimonis@hs.uci.edu](mailto:vkimonis@hs.uci.edu)

## 24 **Abstract**

### 25 **Background**

26 VCP disease, also known as multisystem proteinopathy (MSP1), is a rare, autosomal dominant,  
27 adult-onset, neuromuscular disease that is caused by variants in the valosin-containing protein  
28 (*VCP*) gene. VCP disease may exhibit one or more of the following primary features: Inclusion  
29 Body Myopathy (IBM), Paget's disease of bone (PDB), Frontotemporal Dementia (IBMPFD),  
30 and Amyotrophic Lateral Sclerosis (ALS). Due to its progressive nature, death normally occurs  
31 in their sixties due to respiratory and cardiac failure. The purpose of this study is to utilize the  
32 Cure VCP Disease patient registry hosted by the Coordination of Rare Diseases at Sanford  
33 (CoRDS) to conduct a prospective natural history study.

### 34 **Methods**

35 Seventy-nine participants enrolled in the patient registry and answered demographic, *VCP*  
36 variant type, Patient-Reported Outcome Measures (PROMs), and Quality of Life (QOL)  
37 questionnaires over the course of three years. We additionally investigated if any sex differences  
38 existed and if genotype-phenotype correlations affected the rate of progression of the varying  
39 clinical manifestations.

### 40 **Results**

41 Overall, participants' mobility declined significantly as the disease progressed. Participants  
42 reported a 0.6% decline in upper extremity function, 1.2% decline in lower extremity function,  
43 and 0.3% decline in cognitive function per year of age. Furthermore, participants reported a 1.6%  
44 decline in upper and lower extremity function and a 0.1% decline in cognitive function per year  
45 of disease duration. The highest PROMs correlations between overall health and lower extremity  
46 function, upper extremity function, fatigue, and the ability to perform vigorous activities.

47 Genotype-phenotype correlations revealed no significant differences except for the absence of  
48 PDB in the *p.Arg159Cys* group.

#### 49 **Conclusion**

50 The VCP CoRDS Registry was found to be a valuable tool for monitoring the QOL in patients  
51 with VCP disease and capturing patient perspectives for future clinical trials.

#### 52 **Keywords**

53 VCP, Inclusion Body Myopathy, Paget's Disease of Bone, Frontotemporal Dementia (IBMPFD),  
54 and Amyotrophic Lateral Sclerosis (ALS), multisystem proteinopathy, Patient-Reported  
55 Outcome Measures (PROMs), and Quality of Life (QOL)

56

57

58

59

60

61

62

63

64

65

66

67

68

69

## 70 **Background**

71 Valosin-containing protein (VCP) disease, otherwise known as inclusion body myopathy (IBM)  
72 associated with Paget disease of the bone (PDB) and frontotemporal dementia (FTD) (frequently  
73 used acronym, IBMPFD), or more recently, multi-system proteinopathy type 1 (MSP1), is a  
74 progressive, debilitating, predominantly autosomal dominant genetic condition, which can affect  
75 the muscle, bone, and/or brain. The condition was first reported in 2000 [1] as a new familial  
76 disorder of limb-girdle type of muscle weakness and skeletal disorganization due to PDB, which  
77 was later identified to be due to heterozygous missense variants in the *VCP* gene mapped to  
78 chromosomal location 9p211-p12 [2-4]. The *VCP* (*p97*) gene encodes for an abundant cytosolic  
79 AAA ATPase with multiple cellular functions. It is involved in the ubiquitin-proteasome system  
80 (UPS), the endoplasmic reticulum-associated protein degradation (ERAD), DNA endosomal  
81 sorting, cell cycle regulation, and autophagy [5-8]. To date, more than 80 missense variants  
82 associated with VCP disease have been identified [6]. At the cellular level, variants lead to the  
83 increased enzymatic activity of AAA ATPase reflecting a gain of function mechanism which  
84 dysregulates protein degradation through ERAD and/or UPS resulting in activation of the ER  
85 stress response [7] resulting in a global disturbance of protein folding [5].

86  
87 Al-Obeidi et al. (2018), reported myopathy (typically IBM) in 90% of studied individuals with  
88 VCP disease, PDB in 42%, and FTD in 30% [8]. IBM manifests as progressive muscle  
89 weakness, difficulty in raising the arms and walking upstairs, and atrophy of the muscles of the  
90 pelvis and shoulder girdle. Histologically, IBM is characterized by rimmed vacuoles containing  
91 protein aggregates of TDP-43 [9]. PDB often consists of an increase in osteoclastic activity  
92 resulting in disorganized bone structure and bone weakness, resulting in fractures and localized

93 arthritis [10]. *VCP* gene variants have also been reported to cause ALS in 10%, Parkinson's  
94 disease in 5%, and cardiomyopathy in up to 27% of patients [8] [11-14]. FTD affects speech  
95 production and recall, comprehension, and personality [13-14]. Owing to the progressive nature  
96 of the disorder, death usually occurs prematurely in the 60s due to respiratory and cardiac failure  
97 [8].

98  
99 Currently, while bisphosphonates can be effectively used to manage PDB, there are no  
100 treatments that can modify the progression of *VCP* disease-associated myopathy or FTD [6].  
101 Medical management includes physical therapy, weight control, respiratory aids, and mechanical  
102 aids such as walkers or wheelchairs [6]. Patients are also recommended to receive regular  
103 surveillance to monitor cardiac, bone, lung, and neurologic function following diagnosis [6].

104  
105 Even though *VCP* disease is now reported in several hundred patients across the globe, there are  
106 limited studies investigating how *VCP* disease affects the quality of life (QOL) of patients over  
107 time. We therefore planned to analyze patient reported data to ascertain the prevalence, age of  
108 onset of different manifestations, and track the progression of mobility, cognitive function, and  
109 pain levels in patients with *VCP* disease.

110

## 111 **Methods**

112 Cure *VCP* Disease, Inc., a patient advocacy group established to unite patients and researchers to  
113 advance treatments and cures for *VCP* disease, collaborated with the Coordination of Rare  
114 Diseases at Sanford (CoRDS), a centralized international patient registry for rare diseases, to  
115 host a patient registry (*VCP* CoRDS Registry). The registry survey contains 143 unique

116 questions related to demographics, diagnosis, age of onset, symptoms, disease progression, pain,  
117 and QOL. The registry participants are prompted to update survey responses annually. Thus, a  
118 longitudinal natural history study over the course of up to three years was established to explore  
119 the progression of QOL symptoms among VCP disease patients. Using data contained in the  
120 registry, we conducted the following analyses: 1) progression of functional abilities, 2) quality of  
121 life correlations, and 3) genotype-phenotype correlations. We compiled the genetic variant and  
122 phenotype responses from the VCP CoRDS Registry for each participant to conduct a genotype-  
123 phenotype comparison for the specific VCP disease variant. We used Excel and SPSS to conduct  
124 one sample t-tests with a 95% confidence interval for the statistical analysis in the genotype-  
125 phenotype comparison (IBM SPSS Statistics, Version 27).

126  
127 For the progression of functional abilities analysis, we extracted from the VCP CoRDS registry,  
128 the responses from three surveys developed by the National Institute of Neurological Disorders  
129 and Stroke (NINDS): lower extremity function (Neuro-QOL Item Bank v 1.0 short form), upper  
130 extremity function (Neuro-QOL Item Bank v 1.0 short form), and cognition function (Neuro-  
131 QOL Item Bank v 2.0 short form) [15]. Each Neuro-QoL survey consists of eight questions  
132 developed to assess upper extremity function (such as their ability to turn a key in a lock, brush  
133 teeth, write with a pen or pencil, open and close a zipper), lower extremity function, and  
134 cognitive function, respectively. These patient-reported outcome measures (PROMS) have been  
135 previously proven to be valuable tools to increase understanding of disease symptoms and  
136 overall quality of life [16-17]. The 5-point Likert scale was applied in these responses to  
137 understand the extent to which participants can perform specific daily functions where a score of  
138 1 is defined as the inability to perform a task while a score of 5 is the ability to complete a task

139 without any difficulty. The total raw scores from the short forms were calculated for lower  
140 extremity function, upper extremity function, and cognitive function. To analyze pain in this  
141 population, we used the pain levels reported in the patient registry on a scale of 0-10 with 10  
142 being the worst pain imaginable. Mild pain was defined as 0-3; moderate pain was 4-6; and  
143 severe pain was 7 or higher on the pain scale. We then compared pain levels and progression of  
144 pain between male and female participants by comparing their pain level with age as well as  
145 disease duration. We applied a linear regression model to observe the progression in mobility,  
146 cognitive function, and pain with age and disease duration.

147

148 Lastly, we analyzed the possible effect of disease progression, pain, and age on QOL.

149 Participants reported their QOL symptoms by answering five questions in the QOL section of the  
150 VCP CoRDS Registry. We converted the participants' responses using a 5-point Likert scale  
151 (where 1 represents poor QOL while 5 represents excellent QOL utilizing their latest responses),  
152 in which those scores were added to a bar chart comparing the latest responses of symptomatic  
153 and pre-symptomatic participants. Mobility and cognitive function were classified according to  
154 the total raw scores provided by the Neuro-QOL surveys. We calculated the Spearman  
155 correlation coefficients to evaluate if any correlations existed between each of the following nine  
156 metrics through a correlation matrix: age, disease progression (lower extremity, upper extremity,  
157 cognitive function, and pain), and QOL factors (vigorous activities, fatigue, general health, pain  
158 interference, and depression). We classified correlations between these factors as strong ( $\pm 0.7-$   
159  $1.0$ ), moderate ( $\pm 0.4-0.6$ ), and weak ( $\pm 0.0-0.3$ ). We utilized the R program to generate a  
160 visually informative heat map, offering a comprehensive depiction and comparison of the  
161 various correlation coefficient magnitudes [R version 4.4.0 (Puppy Cup) prerelease versions].


162 **Results**

163 Demographic information was collected from the VCP CoRDS Registry (Table 1). Seventy-nine  
 164 participants [males (N=35, 44.3%), females (N=39, 49.4%), and five unreported sex (6.3%)]  
 165 contributed to this study and approximately 89% of the participants reported themselves as  
 166 ‘White’ with 4% ‘Asian’, and 6% ‘Mixed or Other’. The average age reported associated with  
 167 diagnosis of muscle weakness, PDB, and dementia was 42.3 years, 47.3 years, and 54.8 years,  
 168 respectively. Seventy-nine participants were registered from nine different countries (Figure 1).  
 169 Most of the participants were from the United States (N=59, 71%), followed by the United  
 170 Kingdom (N=5, 6%) and Australia (N=5, 6%). Four participants did not indicate their country of  
 171 submission.

**Table 1. Demographic Data of Participants (\* prevalence)**

| <b>Total Participants (N=79)</b>             | <b>Mean Age ± SD (years)</b> | <b>Range (years)</b> |
|--|------------------------------|----------------------|
| Age at enrollment (N=77)                     | 51.6 ± 11.8                  | 21-77                |
| Age of symptomatic onset (N=57)              | 42.4 ± 11.6                  | 5-71                 |
| Age at diagnosis (N=69)                      | 46.8 ± 11.5                  | 17-73                |
| Age of onset of muscle weakness (N=60, 76%*) | 42.3 ± 9.6                   | 12-67                |
| Age at onset of Paget's disease (N=18, 23%*) | 47.3 ± 9.4                   | 30-68                |
| Age at onset of dementia (N=9, 11%*)         | 54.8 ± 16.3                  | 25-71                |
| <b>Participant Sex (N= M: F)</b>             | 35:39                        | 5-77                 |
| <b>Racial Categories</b>                     | <b>N (%)</b>                 |                      |
| White  | 63 (89%)                     | 21-73                |
| Asian  | 3 (4%)                       | 50-67                |
| Black or African American                    | 1 (1%)                       | 54                   |
| Mixed or Other                               | 4 (6%)                       | 27-77                |
| <b>Ethnicity</b>                             |                              |                      |
| Hispanic or Latino                           | 6 (10%)                      | 56-62                |
| Non-Hispanic                                 | 54 (90%)                     | 21-77                |






172 **Figure 1. Demographic Data of Participants by Country of Residence.** Seventy-nine  
173 participants from nine different countries participated in the study. Fifty-nine participants (75%)  
174 registered in the United States. One participant (1%) did not indicate country of submission.

175  
176 Of the total number of participants registered, nine participants were pre-symptomatic (Figure  
177 S1). A pre-symptomatic participant is defined as someone who has a variant on the *VCP* gene  
178 but has neither been diagnosed with nor experienced a *VCP*-related clinical symptom. Sixty-six  
179 (84%) participants were symptomatic, meaning the participant either reported a clinical diagnosis  
180 or *VCP*-related clinical symptoms in the registry (Figure 2). Three participants indicated “other”  
181 under physical diagnosis, however, did not specify their comorbidities. The status of four  
182 participants is unknown. Out of the 62 symptomatic participants that reported a phenotype  
183 diagnosis, the most common clinical feature reported was myopathy (N=52, 83.9%); notably, of  
184 these patients, twenty participants (32.3%) reported isolated myopathy and thirteen participants

185 (21.0%) reported both myopathy and PDB (Figure 2). The second most common physical  
186 diagnosis was PDB (N=18, 29.0%). In addition, nine participants reported FTD (14.5%), six  
187 participants reported peripheral neuropathy (9.7%), nine participants reported cataracts (14.5%),  
188 four participants reported cardiomyopathy (6.5%), three participants reported ALS (4.8%), and  
189 one participant reported Parkinson's disease (1.6%). Sixty-seven participants reported their mean  
190 age of diagnosis for VCP disease as 49 years (range 23-73). Of the symptomatic group, twelve  
191 participants (17.9%) were diagnosed between the ages of 31-40 years, twenty-one (31.3%) were  
192 diagnosed between the ages of 41 years and 50 years, and twenty participants (30%) were  
193 diagnosed between the ages of 51 years and 60 years. A large majority of participants reported  
194 symptom-onset during adulthood; however, one participant reported having symptoms starting at  
195 the age of 12 years while another participant was pre-symptomatically diagnosed at the age of 17  
196 years (Figure S2). Among the 56 participants who reported their age of first symptom onset, the  
197 most common age range was between 31-40 years (N=20, 36%), closely followed by 41-50 years  
198 (N=17, 30%). In this cohort, the average time from symptom onset to establishment of the  
199 diagnosis was 6.8 years with the longest duration of 29 years (Figure S2).



200 **Supplemental Figure 1. Quality of Life - A Comparison of Pre-Symptomatic vs.**  
 201 **Symptomatic VCP Patients.** A comparison between pre-symptomatic (orange, N=9) and  
 202 symptomatic (green, N=66) participants when asked five QOL questions was conducted. **(a)**  
 203 Participants' responses when asked about their general health. **(b)** Participants' responses when  
 204 asked if their health limits them in doing vigorous activities. **(c)** Participants' responses when  
 205 asked if they feel depressed. **(d)** Participants' responses when asked how often they feel tired. **(e)**  
 206 Participants' responses when asked how much pain interfered with their enjoyment of life.



215 **Supplemental Figure 2. Demographics.** (a) Age of diagnosis of participants with VCP disease  
216 (N=67). (b) Age of first symptom onset in VCP disease participants (N=56). Each slice  
217 represents a specific age range.

218

### 219 **Genotype-Phenotype Comparison**

220 The genotype-phenotype analysis of this cohort revealed phenotypic diversity in VCP disease in  
221 relation to the variant group and the corresponding clinical features reported (Table 2, S1).  
222 Among the 49 participants (mean age 52.5 years) who reported their *VCP* variant, 17 (35%)  
223 reported the *p.Arg155His, c.464G>A*, variant, making this the most prevalent variant in this  
224 cohort (Table 2, S1). Not surprisingly, all the phenotypes were represented in this *p.Arg155His*  
225 cohort (myopathy, PDB, dementia, ALS, peripheral neuropathy, Parkinson's disease, and  
226 cataracts); Parkinson's disease was reported by only one participant in the R155H variant group  
227 in 5.6% (2%), ALS was only reported by two (4.1%) participants with *p.Arg155His* variant and  
228 was not reported in the other variant groups. The earliest reported age of onset was by a 27-year-  
229 old participant with myopathy and peripheral neuropathy with the *p.Arg155His, c.464G>A*  
230 variant (Table S1). The second most prevalent variant group with 8 participants was the  
231 *p.Arg155Cys, c.463C>T* group. Among all the variant groups, myopathy was identified in 36  
232 participants [73.5%, 43.1 ± 8.8 years], making it the most common phenotype. The only possible  
233 notable genotype-phenotype correlations identified was the absence of PDB in the *p.Arg159Cys,*  
234 *c.475C>T* variant group.

**Table 2. VCP gene variants in current cohort**

| <b>Variant group</b>   | <b>N=49 (%)</b>       |
|------------------------|-----------------------|
| p.Arg155His, c.464G>A  | 18 (36.2%)            |
| p.Arg155Cys, c.463C>T  | 6 (17.0%)             |
| p.Arg159His, c.476G>A  | 5 (6.4%)              |
| p.Arg93Cys, c.277C>T   | 3 (8.5%)              |
| p.Arg159Cys, c.475C>T  | 4 (8.5%) <sup>b</sup> |
| p.Arg191Gln, c.572G>A  | 3 (6.4%)              |
| p.Leu198, c.Trp 593T>G | 2 (4.3%)              |
| p.Gly97Glu, c.290G>A   | 1 (2.1%)              |
| p.Ile369Thr, c.1106T>C | 1 (2.1%)              |
| p.Arg95Gly, c.283C>G   | 1 (2.1%)              |
| p.Asn387Thr, c.1160A>C | 1 (2.1%)              |
| p.Gly128Ala, c.383G>C  | 1 (2.1%)              |
| p.Gly782Ala, c.2345G>C | 1 (2.1%)              |

235

236

237 **Supplemental Table 1: Genotype—phenotype comparison data of clinical features**  
238 **symptomatic patients in different variant groups. (Please see appendix)**

239 Abbreviations: *N* = sample number, *NA* = not applicable; No participants reported to have the  
240 corresponding symptoms in the phenotype categories.

241

242 **Progression of Functional Abilities**

243 *Upper and Lower Extremity Function*


244 We assessed the mobility of the sixty-seven participants who completed all the questions in the

245 Neuro-QoL upper and lower extremity function surveys by analyzing the responses separately.

246 Examples of PROM questions pertaining to upper extremity function include the ability to turn a

247 key in a lock, brush teeth, write with a pen or pencil, open and close a zipper, etc. Affected


248 participants showed an overall decline of 0.58% in upper extremity function with every 1-year  
249 increase of age (slope=-0.38,  $R^2=0.23$ ) (Figure 3a). Participants also displayed an overall decline  
250 of -1.57% in upper extremity function for every 1 year of disease progression (slope=-0.63,  
251  $R^2=0.32$ ) (Figure 3b). Similar trends were seen in males and females with age ( $p=0.45$ ) and  
252 disease duration ( $p=0.57$ ).



253 **Figure 3. Upper Extremity Function Progression.** A scatter plot was created to illustrate the  
254 correlations between (a) age and (b) disease duration relative to the total reported raw score for  
255 upper extremity function. The solid lines indicate progression within a singular participant over  
256 time for data with multiple submissions whereas the dashed lines indicate overall progression in  
257 males (blue) and females (pink) using the latest submission. Both male (blue squares) and female  
258 participants (pink circles) showed a rapid decline in their overall mobility with increasing age and  
259 also disease duration.

260  
261 Both sexes exhibited similar trends in lower extremity function with increasing age with an  
262 overall decline of 1.19%, (Figure 4a). Participants reported an overall decline in lower extremity  
263 function as their disease progressed (slope=-0.64,  $R^2=0.27$ ) (Figure 4b). Females demonstrated a  
264 more rapid decline (slope=-0.66,  $R^2=0.29$ ) than males (slope=-0.59,  $R^2=0.25$ ). Participants also

265 rated their upper extremity function by answering PROM questions such as their ability to run  
266 errands, get in and out of a car, step up and down curbs, and walk for at least 15 minutes.




267 **Figure 4. Lower Extremity Function Progression.** A scatter plot was created to illustrate the  
268 correlations between (a) age and (b) disease duration relative to the total reported raw score for  
269 lower extremity function. The solid lines indicate progression within a singular participant over  
270 time for data with multiple submissions whereas the dashed lines indicate overall progression in  
271 males (blue) and females (pink) using the latest submission. Both male (blue squares) and female  
272 participants (pink circles) showed a rapid decline in their overall mobility with increasing age  
273 and disease duration.

#### 274 275 *Cognitive Function*

276 Next, we assessed the cognitive function of the seventy participants who completed the Neuro-  
277 QoL cognitive function survey. PROM questions to assess cognitive function include ability to  
278 perform specific tasks such as reading and following complex instructions, concentrating, and  
279 paying attention. Similar to the technique used in the calculation of functional ability, we  
280 calculated the total raw scores and then created a scatter plot to show the correlation with age in  
281 years (Figure 5). Both males (N=33) and females (N=37) displayed an overall gradual decline in  
282 cognitive function, however females showed a slightly more rapid decline (slope=-0.18,  
283  $R^2=0.06$ ) compared to males (slope=-0.06,  $R^2=0.01$ ) (Figure 5a). Overall, there is no correlation



284 between cognitive function and disease duration for every year of age, regardless of sex  
285 ( $R^2=0.01$ ) (Figure 5b).



286 **Figure 5. Cognitive Function Progression.**

287 A scatter plot was created to illustrate the correlations between (a) age and (b) disease duration  
288 relative to the total reported raw score for cognitive function. The solid lines indicate progression  
289 within a singular participant over time for data with multiple submissions whereas the dashed  
290 lines indicate overall progression in males (blue) and females (pink) using the latest submitted  
291 value. Both male (blue squares) and female participants (pink circles) showed a decline in their  
292 overall cognitive abilities with increasing age whereas little to no decline with increasing disease  
293 duration.


294

### 295 *Pain Level*


296 Based on the overall pain scale, 13.0% of participants reported no pain, 38.2% reported mild  
297 pain (pain score 1-3), 35.3% reported moderate pain (pain score 4-6), and 13.2% reported severe  
298 pain (pain score 7 or higher). Furthermore, 80.3% of symptomatic participants reported pain  
299 sometimes, often, or always interferes with their enjoyment of life (Figure S2). Using the latest  
300 participant data entries, we created a bar graph comparing the frequency of reported pain levels  
301 between male (N=34) and female (N=38) participants (Figure 6). There was a wide distribution  
302 in pain levels among participants, with 2 being the most frequent score for females (22.9%) and

303 3 being the most frequent score for males (24.2%), according to the latest submission.

304 Interestingly, females showed a gradual decrease in pain (slope=-0.03,  $R^2=0.03$ ), whereas males  
305 showed an increase in pain with increasing age (slope=0.08,  $R^2=0.13$ ) (Figure 7a). Most male  
306 and female participants with multiple entries reported no change in pain, while some reported an  
307 increase in pain.



308 **Figure 6. Comparison of Pain Levels in Males and Females.** The bar graph shows the  
309 distribution of pain scores amongst males (blue) and females (pink). Pain levels of participants  
310 were recorded over the course of up to three years with the latest score being used for analysis.  
311 the pain scores ranged from 0-10, a value of 0 indicating no pain while a value of 10 indicating  
312 the worst pain imaginable.



313 **Figure 7. Pain Level Progression.** A scatter plot was generated to illustrate the correlations  
314 between age (a) and disease duration (b) relative to the total reported raw score for pain. The  
315 solid lines indicate progression within a singular participant over time for data with multiple  
316 submissions whereas the dashed lines indicate overall progression in males (blue) and females  
317 (pink) using the latest submission. Male participants (blue squares) showed an incline in their  
318 overall pain levels with increasing age and disease duration whereas female participants (pink  
319 circles) showed a decline in pain levels with increasing age but an increase in pain levels as the  
320 disease progressed.

321

## 322 **Quality of Life**

### 323 **Quality of Life in Symptomatic Participants**

324 Seventy-five participants completed the five QOL survey questions in the VCP CoRDS Registry  
325 (9 pre-symptomatic, 66 symptomatic) (Figure S2). Among symptomatic participants, 88%  
326 (57/66) of symptomatic participants reported that their health often or always limits doing  
327 vigorous activities, 76% (51/66) reported that they often or always felt tired, 55% (36/66)  
328 reported fair or poor general health, 45% (29/66) reported that pain always or often interfered  
329 with their enjoyment of life, and 29% (19/66) reported being always or often depressed. The

330 responses of pre-symptomatic patients are included in the graph for reference, but due to the low  
331 numbers, a comparison was not calculated.

332

### 333 **Quality of Life, Disease Progression, and Age Correlations:**

334 Moderate positive correlations were found between vigorous activities and upper (0.57) and  
335 lower (0.63) extremity function, suggesting that musculoskeletal health and functional ability  
336 across different body areas for patients with VCP disease has a negative impact on the intensity  
337 of physical exercise. Furthermore, the moderate positive correlation between pain interference  
338 and fatigue (0.63) implies that as pain interference increases, there is a negative impact on the  
339 enjoyment of life for individuals experiencing these symptoms. Depression and fatigue (0.46),  
340 and pain interference and depression (0.41) also had positive correlation. This suggests that those  
341 who often felt that pain interfered with their enjoyment of life also reported feeling depressed  
342 and those who reported often having feelings of depression also reported greater feelings of  
343 tiredness. This connected relationship emphasizes the concept that perceptions of pain  
344 interference, feelings of depression, and tiredness are closely intertwined, highlighting the  
345 complexity of these emotional and physical states VCP patients experience. Additionally, several  
346 moderate positive correlations were found between overall general health and other factors:  
347 lower extremity function (0.63), upper extremity function (0.46), fatigue (0.46), and vigorous  
348 activities (0.46). Moderate negative correlations were found between pain level and fatigue (-  
349 0.57), pain level and pain interference (-0.56), lower extremity function and age (-0.49), and  
350 vigorous activities and age (-0.41) while all other correlations were weak. This analysis provided  
351 a sophisticated understanding of the complex relationships among the factors under

352 investigation. These findings emphasize the significance of considering multiple perspectives of  
353 VCP patients to improve affected individuals' overall well-being and quality of life.

354  
355 When comparing age, disease progression and QOL factors, a strong correlation was discovered  
356 between lower extremity function and upper extremity function (0.85). Additionally, moderate  
357 correlations were found between lower extremity function and vigorous activities (0.63). These  
358 findings are consistent with the known progression of muscle disease in both the upper and lower  
359 skeletal muscles. When analyzing patients' determination of their overall general health, lower  
360 extremity function had the strongest correlation (0.63), with upper extremity function, vigorous  
361 activities and fatigue also revealing a moderate correlation to overall general health (0.46  
362 respectively). Loss of muscle function has a direct effect on a person's ability to complete daily  
363 activities and participate in vigorous activities, so these findings are not surprising. Our data  
364 revealed moderate correlations between age and lower extremity function as well as vigorous  
365 activities, while pain, general health, cognition function, and fatigue showed weak correlations  
366 with age.


367

### 368 **Heat Map depicting Quality of Life correlations between key health factors.**

369 We studied correlations between pain level, cognitive function, lower extremity, upper  
370 extremity, general health, vigorous activities, pain interference, fatigue, depression factors that  
371 were evaluated in the questionnaire. The larger and darker the circle around the correlation value,  
372 the stronger the correlation between the two variables (Figure 8).

373

374 A patient's pain level displayed a moderate negative correlation to both fatigue (-0.57) and how  
 375 often pain interfered with their enjoyment of life (-0.56). In other words, as pain level increased,  
 376 a patient was more likely to report being tired and having pain interfere with their enjoyment of  
 377 life. Strong evidence of a relationship between pain and tiredness, and between pain interference  
 378 and depression. Interestingly, fatigue and pain interference have the same correlation to pain  
 379 level suggesting the significance of both pain and fatigue in the enjoyment of life. Moreover, a  
 380 significant percentage of VCP patients reported experiencing fatigue at high levels, with 76%  
 381 (51/66) reporting that they often or always felt tired and 88% (57/66) of symptomatic  
 382 participants reporting that their health often or always limits doing vigorous activities. A  
 383 correlation analysis between fatigue, pain inference, and depression further revealed a moderate  
 384 correlation between all three of these factors [pain inference and fatigue (0.63), fatigue and  
 385 depression (0.46), and pain inference and depression (0.41)].



396 **Figure 8. Quality of Life.** This is a representation of a heat map signifying the correlation  
397 between the first five variables, which were measured during the study. General Health,  
398 Vigorous Activities, Pain Interference, Tiredness, Depression were factors that were evaluated  
399 from our questionnaire. The scale on the right represents the direction and intensity of the  
400 correlation. The larger and darker the circle around the correlation value, the stronger the  
401 correlation between the two variables.

402

### 403 **Overall Summary of Findings:**

404 Among the 79 participants, myopathy was the most prevalent phenotype (84.0%), followed by  
405 PDB (43.4%), FTD (12.9%), ALS (4.8%), and Parkinson's disease (1.6%). Regarding the  
406 disease progression studies, participants revealed a significant decline of 0.6% in upper extremity  
407 function, 1.2% in lower extremity function, and 0.3% in cognitive function per year of age.  
408 Participants also revealed a 1.6% decline in upper and lower extremity function and a 0.1%  
409 decline in cognitive function per year of disease duration. This study highlights the high  
410 frequency of pain and the impact of fatigue on the quality-of-life aspects, such as depression and  
411 enjoyment of life in this patient population. Interestingly, the strongest correlation concerning  
412 patient reported general health was not age but lower extremity function. The *c. 464G>A*,  
413 *p.R155H* VCP variant was reported as the most prevalent variant group with the highest number  
414 of phenotypic characteristics. No obvious genotype-phenotype correlations for VCP disease  
415 phenotypes were noted.

416

417

418

## 419 **Discussion**

420 Studying the natural history of a disease is important because it provides critical information on  
421 how the disease affects a patient's daily life, understanding disease progression, which can thus  
422 be useful in creating preventative interventions, and permits studying the effects of therapeutic  
423 interventions. The inclusion of real-world evidence in the 21<sup>st</sup> Century Cures Act and the use of  
424 PROMs in the FDA guidance in drug development elevates the need to evaluate natural history  
425 from the patient's perspective early in the drug discovery process [17, 18].

426

### 427 *Influence of Genotype on Phenotype*

428 Valosin-containing protein (*VCP*) variants can cause adult-onset proximal myopathy, which  
429 leads to upper and lower extremity weakness, axial myopathy, scapular winging, PDB and  
430 frontotemporal dementia (IBMPFD) [4, 19-21]. The most common phenotype was myopathy  
431 with the mean age of onset of 43.1 years as previously reported [22], followed by PDB with an  
432 average age of onset of 44.8 years. *VCP* has several functions: it is involved in cell division,  
433 repairing DNA damage, membrane fusion, and reassembling structures in cells post-division. It  
434 is also involved as an ATPase in autophagy and cell degradation, including ubiquitin-related  
435 cellular processes [5]. The *VCP* enzyme consists of the N domain and D1 and D2 domains,  
436 which are the ATPase modules. The D1 and D2 domains of *VCP* form a homohexamer in a  
437 head-to-tail ring structure, which allows the N domain to undergo conformational changes when  
438 ubiquitin-binding occurs. Missense variants in the *VCP* gene that cause IBMPFD can disrupt the  
439 double-psi barrel (R95G), four-stranded beta-barrel (R155C, R155H, R155P), or the flexible  
440 linker (R191Q). Most of the variants are in the N-terminal domain, which has the function of  
441 binding cofactors and ubiquitylated proteins [4]. We reported 13 unique variants in this



442 cohort. The R155 codon is a mutational hotspot reported in 46% of the VCP variants reported in  
443 our study; the most prevalent is R155H, followed by R155C, as reported previously [4, 21].  
444 Based on our genotype-phenotype comparisons study, we did not observe any significant  
445 correlations.

446

#### 447 *Disease Progression*

448 A notable decline in mobility was detected in participants with VCP disease, exhibiting a  
449 negative correlation with both advancing age and prolonged disease duration. The presence of  
450 comorbidities such as myopathy, PDB, ALS, and Parkinson's disease further exacerbates the  
451 decline in mobility seen in those with VCP disease. The variability in decline of mobility due to  
452 VCP myopathy aligns with the documented progression pattern in limb-girdle muscular  
453 dystrophy (LGMD), which could be characterized by a heterogeneous onset of muscle weakness  
454 affecting the pelvic and shoulder girdles, typically manifesting in adolescence or early adulthood.  
455 The progression of LGMD varies widely, with some patients experiencing rapid deterioration  
456 while others show a slower decline [23, 24]. Variability in progression rate is similarly observed  
457 in ALS, particularly among patients with SOD1 mutations. For instance, individuals harboring  
458 the SOD1 A4V mutation often experience a more aggressive disease trajectory, with a median  
459 survival of approximately 1.2 years, in contrast to the 6.8 years observed for other SOD1  
460 mutations [25]. Studies emphasize the importance of early clinical markers, including changes in  
461 functional scores and respiratory function, to elucidate disease trajectories and inform therapeutic  
462 strategies. These insights highlight the necessity of an integrated approach to the clinical  
463 management of VCP disease, addressing both the primary disorder and its associated co-  
464 morbidities to enhance patient outcomes and quality of life.

465 Overall, both male and female participants displayed slight cognitive impairments with age. This  
466 is consistent with previous studies of families with patients who displayed cognitive impairments  
467 at a mean age of 56 years [8]. Following a detailed investigation of the link between aging and  
468 cognitive performance, our findings demonstrated a steady deterioration in cognitive function  
469 with increasing age. Previous research confirms this by concluding a negative connection  
470 between age and cognitive performance across a variety of activities, including memory,  
471 processing speed, and executive functioning [26]. The research goes into neuroimaging studies,  
472 which highlight structural and functional changes in the aging brain, notably in memory and  
473 information processing areas [26]. According to another study, the aging brain experiences  
474 complex interactions and changes that affect many cognitive processes other than memory and  
475 information processing. Altogether, these investigations confirm a similar trend: an individual's  
476 cognitive capacity tends to deteriorate with age. In addition to identifying potential treatment and  
477 preventive methods to reduce age-related cognitive loss, it is critical to underline the importance  
478 of multidisciplinary research in understanding the complex nature of cognitive aging [27].

479

#### 480 *Pain Implications*

481 In analyzing the reported pain levels, males reported more pain with the progression of the  
482 disease (slope = 0.08 versus -0.03,  $p < 0.01$ ) with advancing age. In other studies, a multitude of  
483 factors, including biological, psychosocial, sex difference, have been proven to influence an  
484 individual's pain, and understanding these factors can serve as a vital foundation for  
485 individualized pain treatment plan [28]. Pain is a common and underappreciated manifestation of  
486 VCP disease and can result from comorbidities such as PDB, which typically affects the lumbar  
487 spine, hips, pelvis and skull [25]. It is important to investigate the presence of PDB to reduce the

488 additional burden since it is readily treatable with bisphosphonates. Interestingly in this cohort,  
489 symptomatic VCP participants with PDB did not report a higher level of pain when compared to  
490 symptomatic VCP participants without PDB (average pain score of 3.2/10, 4.1/10, respectively).  
491 These results may suggest that patients may have undiagnosed PDB or that some patients with  
492 PDB may be receiving treatment to address their pain. We further analyzed similarities among  
493 patients who reported high levels of pain, and the presence of myopathy was the only common  
494 factor we discovered. Interestingly, a greater percentage of VCP participants without PDB  
495 reported a moderate to high level of pain (4 or higher) when compared to VCP participants with  
496 PDB (55% 26/45, 37% 6/16). These results suggest that PDB may not be the main source of pain  
497 and that other disease-specific causes of pain exist in VCP disease, such as muscle pain or  
498 neuropathy. Thus, these results indicate that the detection and treatment of an individual's pain  
499 needs to be part of a VCP patient's clinical care plan; future studies are needed to determine the  
500 causes of pain in VCP patients.

501

### 502 *Sex Considerations*

503 Other research studies indicate that males may have a more noticeable perception of decline in  
504 physical activity as they are unable to reach their activity goals, and this perception of change  
505 may explain the steeper reported decline in lower extremity function reported in males (slope=  
506  $-0.52$ ,  $R^2=0.34$ ) compared to the females (slope= $-0.41$ ,  $R^2=0.22$ ). One particular study found a  
507 difference in motivating factors for adult physical activities amongst the sexes [22]. Another  
508 study found that while males were motivated by mastery of physical activity, females were  
509 motivated by the psychosocial wellbeing component of exercise [26]. Additionally, previous  
510 studies have demonstrated that males were less likely to report depression than females, despite

511 more males completing suicide due to the gravity of their deteriorating mental health [27].  
512 However, we cannot ignore the potential biological differences between males and females and  
513 the prevalence of depression. There is evidence that estrogen acting as a psycho-protective  
514 component in the body, and the conversion of testosterone to estrogen in males mediates a  
515 protective action throughout life. While estrogen levels fluctuate with the premenstrual cycle in  
516 females, testosterone has a more consistent level in males [27]. Cognitive function results from  
517 this cohort showed a slightly more rapid decline in females (slope=-0.1782,  $R^2=0.06$ ) compared  
518 to males (slope=-0.0622,  $R^2=0.01$ ), but a low incidence of dementia reported in this cohort may  
519 influence these findings.

520

#### 521 *Comparing Quality of Life Parameter Correlations*

522 In a thorough investigation conducted by Yamada et al., cross-sectional studies of the data  
523 unveiled significant correlations between measures of pain and fatigue/tiredness [29]. Although  
524 the study's main focus was on the relationship between pain and tiredness symptoms over time in  
525 people with musculoskeletal disorders, it is crucial to interpret these results in the context of the  
526 larger body of research on the relationship between pain and fatigue. Strong evidence of a  
527 relationship between pain and tiredness was found in our dataset; this relationship graphically  
528 displayed in a heatmap. This numerical insight not only underscores the significance of our  
529 study's specific analysis but also contributes valuable quantitative evidence to the broader body  
530 of research affirming the intricate relationship between pain and fatigue.

531 According to Linton et al.'s analysis, there is a clear relationship between pain and depression,  
532 which calls for a complex understanding of their interaction within the therapeutic framework  
533 [30]. Within our dataset there was a significant relationship between pain interference and

534 depression. These results highlight the necessity of further research efforts to thoroughly  
535 investigate this association, clarifying the importance for improving therapeutic approaches.  
536 Fatigue or exhaustion is a widespread issue in both community and medical settings, and there is  
537 a strong association with depression. The correlation between enhanced work performance and  
538 improved energy underscores the importance of addressing fatigue in the context of depression.  
539 In our study, an analysis of depression and tiredness/fatigue revealed a significant association  
540 meriting the need for further investigation [31].

541  
542 Paterson et al.'s study of generalized physical activity and functional limitations demonstrated  
543 that regular physical activity is associated with a reduced risk of functional limitations,  
544 particularly in the older age group [32]. In a preclinical study of VCP disease, exercise training  
545 in mice with the *Arg155His* Vcp variant found that there was an improvement with uphill  
546 exercise [33]. Korb et al.'s recommendations of the standard of care for patients with VCP  
547 disease acknowledges that exercise has a positive effect on individuals with FTD [34]. A recent  
548 study on resistance respiratory exercise in subjects with VCP myopathy showed that the  
549 maximum inspiratory pressure increased significantly over the 32 week course of the resistance  
550 training compared to the baseline [35]. The effects of generalized exercise training however have  
551 not been studied and is a significant unmet need because of the absence of clear guidelines on  
552 exercise training in the VCP myopathy patient population.

553

#### 554 *Patient Perspective and Management of Care*

555 Quality of life is imperative to navigating a patient's health. Treatment options are catered to  
556 maximizing a patient's quality of life, and therefore understanding patient perspectives is integral

557 to optimizing patient care [36]. In chronic diseases of neurological or musculoskeletal  
558 disabilities, it has been demonstrated that psychological impacts may lead to a decline in the  
559 QOL of a patient [37-38]. Additionally, chronic illnesses like VCP disease may increase the  
560 prevalence of depression. Routine management of chronic disease warrants depression  
561 screenings and management of pain as patients progress through life with their diagnosis [38].  
562 To gain a better understanding of patient perspectives in VCP disease, we analyzed the responses  
563 to better understand how fatigue, pain, and depression directly impacted their daily life. A  
564 patient's pain level displayed a moderate negative correlation to both fatigue (-0.57) and how  
565 often pain interfered with their enjoyment of life (-0.56). In other words, as pain level increased,  
566 a patient was more likely to report being tired and having pain interfere with their enjoyment of  
567 life. Interestingly, fatigue and pain interference have the same correlation to pain level  
568 suggesting the significance of both pain and fatigue in the enjoyment of life. Moreover, a  
569 significant percentage of VCP patients reported experiencing fatigue at high levels, with 76%  
570 (51/66) reporting that they often or always felt tired and 88% (57/66) of symptomatic  
571 participants reporting that their health often or always limits doing vigorous activities. A  
572 correlation analysis between fatigue, pain inference, and depression further revealed a moderate  
573 correlation between all three of these factors [pain inference and fatigue (0.63), fatigue and  
574 depression (0.46), and pain inference and depression (0.41)], suggesting that these symptoms  
575 may be interrelated and should be monitored throughout the life of a VCP patient. The inclusion  
576 of a mental health section in the VCP care guidelines further demonstrates the importance of  
577 including psychological health in a VCP patient's overall care plan [34].

578

579

## 580 **Limitations and Future Directions**

581 Understanding the mechanisms of complex traits through genotype-phenotype comparisons can  
582 be limiting because there can be multiple genetic and environmental factors that can contribute to  
583 the differences. Understanding interactions between modifier genes and variants on the gene-of-  
584 interest, epigenetics, and environmental factors that lead to certain phenotypes are factors that  
585 should be taken into consideration [21]. The phenotypic diversity of VCP disease is not  
586 necessarily due to the specific types of VCP variants [8]. Patients with the same *VCP* variant  
587 who are in the same family can present with different phenotypes and clinical manifestations.  
588 Other environmental or genetic modifiers that have yet to be investigated [24]. Prior studies  
589 have shown a correlation of the apolipoprotein-E (*APOE4*) allele as a potential VCP modifier  
590 gene [39]. VCP patients with one or more *APOE4* alleles had dementia as a phenotypic  
591 characteristic. Based on these studies, modifier genes and potential interactions with VCP such  
592 as *APOE4*, *NF1*, among others should be accounted for in future studies to better understand  
593 their effects on phenotype along with VCP variants [39]. Our group has also indicated that the  
594 R159C variant is associated with a lower incidence of PDB [16].

595  
596 While the PROMs are very useful in understanding a patient's perspective of disease and  
597 monitoring their longitudinal progression, there are limitations to this data. Because PROMs are  
598 subjective, there are many parameters that can influence the subject's response. Depending on  
599 how patients have been feeling, even days leading up to the questionnaire, can influence their  
600 general perspective of how they answer the survey questions. Moreover, there can be variation in  
601 assessment on a day-to-day basis since the time period for this questionnaire is 7 days. In  
602 addition, every subject's idea of items such as "vigorous activities", "depression", "general

603 health”, and “pain” are subjective and based on their perception. In addition, participants have  
604 subjective levels of pain tolerance at baseline. Moreover, the progression of the disease does not  
605 have the same initial baseline for the participants, as the disease duration is unique for each  
606 participant. Therefore, progression is relative to the patient’s disease progression. For a more  
607 complete disease understanding and natural history, PROMS should be complemented with  
608 clinical examination, diagnostic imaging, and clinical diagnosis.

609  
610 Analyzing the patient-reported progression of VCP disease can provide great insight into its  
611 clinical manifestations; however, more longitudinal data is needed. While we were able to  
612 observe the overall trend in cognitive function, mobility, and pain in this study, only 17  
613 participants reported unique results two or more times. most participants only reporting one data  
614 entry. This limited our ability to report on an individual’s reported change over time. Retrieving  
615 additional data entries from existing participants will provide a better understanding of the  
616 disease progression. In addition, including more pre-symptomatic participants with a VCP  
617 disease variant will allow the monitoring of disease progression longitudinally.

618 Another limitation is that participants did not submit answers to all survey questions due to the  
619 protocol management by the internal review board at Sanford Research. This protocol reviewed  
620 by the review board at Sanford Research allows subjects the option to omit questions which they  
621 do not feel comfortable answering. While this protocol may eliminate erroneous answers from  
622 patients and increase overall registry enrollment, not having all answers completed leads to  
623 challenges in conducting correlation analysis, including having to exclude some participants  
624 from calculations entirely.

625



626 Increasing the sample size of the cohort to include statistically significant data in VCP genotype-  
627 phenotype comparisons can help to analyze the progression in participants with other  
628 comorbidities such as ALS, PDB, and peripheral neuropathy. This could provide better insight as  
629 to how other conditions impact the severity of QOL symptoms amongst participants with VCP  
630 disease. Moreover, collecting data for a longer period of time will allow for increased data  
631 consistency and the monitoring of the long-term progression of VCP phenotypic manifestations.  
632 As more responses are collected over time in the VCP CoRDS Registry, further data analysis can  
633 be conducted, allowing for a longer span of time to understand the correlation of how QOL  
634 changes over time with disease progression.

635

## 636 **Conclusion**

637 Patient registries are valuable tools in improving clinical care and setting future research  
638 direction by including the patient voice, capturing natural history data, and elevating the QOL of  
639 patients. The VCP CoRDS Registry was found to be a valuable tool for monitoring the quality of  
640 life in patients with VCP disease. The results of this study could be a useful tool in monitoring  
641 the natural history progression of upper extremity function, lower extremity function, and  
642 cognitive function in the VCP patient population. This study indicates that patient-driven  
643 registries such as CoRDS can be used to monitor disease progression in rare diseases on a global  
644 scale.

645

## 646 **Declarations**

## 647 **Ethics Approval and Consent to Participate**

648 Written informed consent was obtained from all individuals. This study was approved by the  
649 University of California Irvine Institutional Review Board (IRB) (#2007-5832).

650

### 651 **Consent for Publication**

652 Written informed consent was obtained from all the subjects included in the study. In the case of  
653 deceased patients, they provided their consents prior to their demise.

654

### 655 **Authors' Contributions**

656 Virginia Kimonis, Allison Peck: Conceptualization, methodology, resources, supervision,  
657 validation, project administration, writing and funding acquisition.

658 Eiman Abdoalsadig: Investigation, writing - original draft, visualization, and validation.

659 Merwa Hamid: Investigation, writing - original draft, visualization, and validation.

660 Leepakshi Johar: Investigation, writing - original draft, and visualization.

661 All authors read and approved the final manuscript.

### 662 **Competing Interests**

663 The authors declare that they have no competing interests.

### 664 **Funding**

665 This work was supported by the Cure VCP Disease, Inc. and the Coordination of Rare Diseases at  
666 Sanford (CoRDS) Research Institute

### 667 **Availability of Data and Materials**

668 The datasets generated during and/or analyzed during the current study are available\_

669 from the corresponding author on reasonable request.

### 670 **Acknowledgments**

671 We thank the participants for their contribution to the study. Our gratitude extends to the Cure  
672 VCP Disease, Inc., Alyssa Mendel, and the Coordination of Rare Diseases at Sanford (CoRDS)  
673 Research Institute, Sioux Falls, S. Dakota for their support with the acquisition and management  
674 of registry data. We are grateful to Regina Im, Vu Luu, Mabel Tang, and Ryan Mahoney for their  
675 contribution to this work.

676

## 677 **References**

678 [1] Kimonis VE, Kovach MJ, Waggoner B, Leal S, Salam A, Rimer L, et al. Clinical and  
679 molecular studies in a unique family with autosomal dominant limb-girdle muscular dystrophy  
680 and Paget disease of bone. *Genet Med.* 2000;2(4):232-41.

681 [2] Tucker WS, Jr., Hubbard WH, Stryker TD, Morgan SW, Evans OB, Freemon FR, et al. A  
682 new familial disorder of combined lower motor neuron degeneration and skeletal  
683 disorganization. *Trans Assoc Am Physicians.* 1982; 95:126-34.

684 [3] Kovach MJ, Waggoner B, Leal SM, Gelber D, Khardori R, Levenstien MA, et al. Clinical  
685 delineation and localization to chromosome 9p13.3-p12 of a unique dominant disorder in four  
686 families: hereditary inclusion body myopathy, Paget disease of bone, and frontotemporal  
687 dementia. *Mol Genet Metab.* 2001;74(4):458-75.

688 [4] Watts GD, Wymer J, Kovach MJ, Mehta SG, Mumm S, Darvish D, et al. Inclusion body  
689 myopathy associated with Paget disease of bone and frontotemporal dementia is caused by  
690 mutant valosin-containing protein. *Nat Genet.* 2004;36(4):377-81.

691 [5] Meyer H, Weihl CC. The VCP/p97 system at a glance: connecting cellular function to  
692 disease pathogenesis. *J Cell Sci.* 2014;127(Pt 18):3877-83.

- 693 [6] Pfeffer G, Lee G, Pontifex CS, Fanganiello RD, Peck A, Wehl CC, Kimonis V. Multisystem  
694 Proteinopathy Due to VCP Mutations: A Review of Clinical Heterogeneity and Genetic  
695 Diagnosis. *Genes (Basel)*. 2022 May 27;13(6):963.
- 696 [7] Rabinovich E, Kerem A, Frohlich KU, Diamant N, Bar-Nun S. AAA-ATPase p97/Cdc48p, a  
697 cytosolic chaperone required for endoplasmic reticulum-associated protein degradation. *Mol Cell*  
698 *Biol*. 2002;22(2):626-34.
- 699 [8] Al-Obeidi E, Al-Tahan S, Surampalli A, Goyal N, Wang AK, Hermann A, et al. Genotype-  
700 phenotype study in patients with valosin-containing protein mutations associated with  
701 multisystem proteinopathy. *Clin Genet*. 2018;93(1):119-25.
- 702 [9] Wehl CC, Temiz P, Miller SE, Watts G, Smith C, Forman M, et al. TDP-43 accumulation in  
703 inclusion body myopathy muscle suggests a common pathogenic mechanism with  
704 frontotemporal dementia. *J Neurol Neurosurg Psychiatry*. 2008;79(10):1186-9.
- 705 [10] Langston AL, Ralston SH. Management of Paget's disease of bone. *Rheumatology*  
706 (Oxford). 2004;43(8):955-9.
- 707 [11] Hubbers CU, Clemen CS, Kesper K, Boddich A, Hofmann A, Kamarainen O, et al.  
708 Pathological consequences of VCP mutations on human striated muscle. *Brain*. 2007;130(Pt  
709 2):381-93.
- 710 [12] Majounie E, Traynor BJ, Chio A, Restagno G, Mandrioli J, Benatar M, et al. Mutational  
711 analysis of the *VCP* gene in Parkinson's disease. *Neurobiol Aging*. 2012;33(1):209 e1-2.
- 712 [13] Nalbandian A, Donkervoort S, Dec E, Badadani M, Katheria V, Rana P, et al. The multiple  
713 faces of valosin-containing protein-associated diseases: inclusion body myopathy with Paget's  
714 disease of bone, frontotemporal dementia, and amyotrophic lateral sclerosis. *J Mol Neurosci*.  
715 2011;45(3):522-31.

- 716 [14] Guyant-Maréchal, L., Laquerrière, A., Duyckaerts, C., Dumanchin, C., Bou, J., Dugny, F.,  
717 Le Ber, I., Frébourg, T., Hannequin, D., & Campion, D. (2006). Valosin-containing protein gene  
718 mutations: clinical and neuropathologic features. *Neurology*, 67(4), 644–651.  
719 <https://doi.org/10.1212/01.wnl.0000225184.14578.d3>
- 720 [15] Cella, D., Lai, J. S., Nowinski, C. J., Victorson, D., Peterman, A., Miller, D., Bethoux, F.,  
721 Heinemann, A., Rubin, S., Cavazos, J. E., Reder, A. T., Sufit, R., Simuni, T., Holmes, G. L.,  
722 Siderowf, A., Wojna, V., Bode, R., McKinney, N., Podrabsky, T., Wortman, K., ... Moy, C.  
723 (2012). Neuro-QOL: brief measures of health-related quality of life for clinical research in  
724 neurology. *Neurology*, 78(23), 1860–1867. <https://doi.org/10.1212/WNL.0b013e318258f744>
- 725 [16] Chan, N., Le, C., Shieh, P., Mozaffar, T., Khare, M., Bronstein, J., & Kimonis, V. (2012).  
726 Valosin-containing protein mutation and Parkinson's disease. *Parkinsonism & related disorders*,  
727 18(1), 107–109. <https://doi.org/10.1016/j.parkreldis.2011.07.006>
- 728 [17] Baumhauer J. F. (2017). Patient-Reported Outcomes - Are They Living Up to Their  
729 Potential? *The New England journal of medicine*, 377(1), 6–9.  
730 <https://doi.org/10.1056/NEJMp1702978>
- 731 [18] Lasiter, L., Campbell, A., Basch, E., Hudgens, S., Stewart, M., Wu, J. J., Leahy, A. B., &  
732 Allen, J. (2020). Use of Patient-Reported Outcomes to Understand & Measure the Patient  
733 Experience of Novel Cell and Gene Therapies. *Therapeutic innovation & regulatory science*,  
734 54(6), 1566–1575. <https://doi.org/10.1007/s43441-020-00184-6>
- 735 [19] Kimonis VE, Mehta SG, Fulchiero EC, Thomasova D, Pasquali M, Boycott K, et al.  
736 Clinical studies in familial VCP myopathy associated with Paget disease of bone and  
737 frontotemporal dementia. *Am J Med Genet A*. 2008;146A(6):745-57.

- 738 [20] Weihl CC, Pestronk A, Kimonis VE. Valosin-containing protein disease: inclusion body  
739 myopathy with Paget's disease of the bone and fronto-temporal dementia. *Neuromuscul Disord.*  
740 2009;19(5):308-15.
- 741 [21] Mehta SG, Khare M, Ramani R, Watts GD, Simon M, Osann KE, et al. Genotype-  
742 phenotype studies of VCP-associated inclusion body myopathy with Paget disease of bone  
743 and/or frontotemporal dementia. *Clin Genet.* 2013;83(5):422-31.
- 744 [22] Orgogozo, V., Morizot, B., & Martin, A. (2015). The differential view of genotype-  
745 phenotype relationships. *Frontiers in genetics*, 6, 179. <https://doi.org/10.3389/fgene.2015.00179>
- 746 [23] LoMauro, A., Gandossini, S., Russo, A., Diella, E., Pistininzi, C., Marchi, E., Pascuzzo, R.,  
747 Vantini, S., Aliverti, A., & D'Angelo, M. G. (2021). Over three decades of natural history of  
748 limb girdle muscular dystrophy type R1/2A and R2/2B: Mathematical modelling of a  
749 multifactorial study. *Neuromuscular disorders: NMD*, 31(6), 489–497.  
750 <https://doi.org/10.1016/j.nmd.2021.02.018>
- 751 [24] Murphy, A. P., Morrow, J., Dahlqvist, J. R., Stojkovic, T., Willis, T. A., Sinclair, C. D. J.,  
752 Wastling, S., Yousry, T., Hanna, M. S., James, M. K., Mayhew, A., Eagle, M., Lee, L. E.,  
753 Hogrel, J. Y., Carlier, P. G., Thornton, J. S., Vissing, J., Hollingsworth, K. G., & Straub, V.  
754 (2019). Natural history of limb girdle muscular dystrophy R9 over 6 years: searching for trial  
755 endpoints. *Annals of clinical and translational neurology*, 6(6), 1033–1045.  
756 <https://doi.org/10.1002/acn3.774>
- 757 [25] Tang, L., Ma, Y., Liu, X., Chen, L., & Fan, D. (2019). Better survival in female SOD1-  
758 mutant patients with ALS: A study of SOD1-related natural history. *Translational*  
759 *Neurodegeneration*, 8(1). <https://doi.org/10.1186/s40035-018-0142-8>

- 760 [26] Salthouse T. A. (2011). Neuroanatomical substrates of age-related cognitive decline.  
761 Psychological bulletin, 137(5), 753–784. <https://doi.org/10.1037/a0023262>
- 762 [27] Raz, N., Lindenberger, U., Rodrigue, K. M., Kennedy, K. M., Head, D., Williamson, A.,  
763 Dahle, C., Gerstorf, D., & Acker, J. D. (2005). Regional brain changes in aging healthy adults:  
764 general trends, individual differences and modifiers. Cerebral cortex (New York, N.Y.: 1991),  
765 15(11), 1676–1689. <https://doi.org/10.1093/cercor/bhi044>
- 766 [28] Fillingim R. B. (2017). Individual differences in pain: understanding the mosaic that makes  
767 pain personal. Pain, 158 Suppl 1(Suppl 1), S11–S18.  
768 <https://doi.org/10.1097/j.pain.0000000000000775>
- 769 [29] Yamada, K., Adams, H., Ellis, T., Clark, R., Sully, C., Lariviere, C., & Sullivan, M. J.  
770 (2022). The temporal relation between pain and fatigue in individuals receiving treatment for  
771 chronic musculoskeletal pain. BMC musculoskeletal disorders, 23(1), 219.  
772 <https://doi.org/10.1186/s12891-022-05162-7>
- 773 [30] Linton, S. J., & Bergbom, S. (2011). Understanding the link between depression and  
774 pain. *Scandinavian journal of pain*, 2(2), 47–54. <https://doi.org/10.1016/j.sjpain.2011.01.005>
- 775 [31] Demyttenaere, K., De Fruyt, J., & Stahl, S. M. (2005). The many faces of fatigue in major  
776 depressive disorder. The international journal of neuropsychopharmacology, 8(1), 93–105.  
777 <https://doi.org/10.1017/S1461145704004729>
- 778 [32] Paterson, D. H., & Warburton, D. E. (2010). Physical activity and functional limitations in  
779 older adults: a systematic review related to Canada's Physical Activity Guidelines. The  
780 international journal of behavioral nutrition and physical activity, 7, 38.  
781 <https://doi.org/10.1186/1479-5868-7-38>

- 782 [33] Nalbandian, A., Nguyen, C., Katheria, V., Llewellyn, K. J., Badadani, M., Caiozzo, V., &  
783 Kimonis, V. E. (2013). Exercise training reverses skeletal muscle atrophy in an experimental  
784 model of VCP disease. *PloS one*, 8(10), e76187. <https://doi.org/10.1371/journal.pone.0076187>
- 785 [34] Korb, M., Peck, A., Alfano, L. N., Berger, K. I., James, M. K., Ghoshal, N., Healzer, E.,  
786 Henchcliffe, C., Khan, S., Mammen, P. P. A., Patel, S., Pfeffer, G., Ralston, S. H., Roy, B.,  
787 Seeley, W. W., Swenson, A., Mozaffar, T., Weihl, C., Kimonis, V., & VCP Standards of Care  
788 Working Group (2022). Development of a standard of care for patients with valosin-containing  
789 protein associated multisystem proteinopathy. *Orphanet Journal of Rare Diseases*, 17(1), 23.  
790 <https://doi.org/10.1186/s13023-022-02172-5>
- 791 [35] Halseth M, Mahoney R, Hsiou J, Jones HN, Kimonis V. Remote respiratory resistance  
792 exercise training improves respiratory function in individuals with VCP multisystem  
793 proteinopathy. *Neuromuscul Disord*. 2024 Jan; 34:68-74.
- 794 [36] Sixma, H. J., Kerssens, J. J., Campen, C. V., & Peters, L. (1998). Quality of care from the  
795 patients' perspective: from theoretical concept to a new measuring instrument. *Health*  
796 *expectations: an international journal of public participation in health care and health policy*,  
797 1(2), 82–95. <https://doi.org/10.1046/j.1369-6513.1998.00004.x>
- 798 [37] Crombez, G., Veirman, E., Van Ryckeghem, D., Scott, W., & De Paepe, A. (2023). The  
799 effect of psychological factors on pain outcomes: lessons learned for the next generation of  
800 research. *Pain reports*, 8(6), e1112. <https://doi.org/10.1097/PR9.0000000000001112>
- 801 [38] Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and Pain Comorbidity: A  
802 Literature Review. *Arch Intern Med*. 2003;163(20):2433–2445.  
803 [doi:10.1001/archinte.163.20.2433](https://doi.org/10.1001/archinte.163.20.2433)



804 [39] Mehta, S. G., Watts, G. D., Adamson, J. L., Hutton, M., Umberger, G., Xiong, S., Ramdeen,  
805 S., Lovell, M. A., Kimonis, V. E., & Smith, C. D. (2007). APOE is a potential modifier gene in  
806 an autosomal dominant form of frontotemporal dementia (IBMPFD). *Genetics in Medicine:*  
807 *official journal of the American College of Medical Genetics*, 9(1), 9–13.  
808 <https://doi.org/10.1097/gim.0b013e31802d830d>

**Supplemental Table 1: Genotype—Phenotype Comparison Data of Clinical Features 238 Symptomatic Patients in Different Variant Groups**

| Mutation group   | N (%)             | Age of onset      |              |             |                   | Age of onset            |              |             |                  | Age of onset       |              |            |                 | Age of onset                  |              |            |                  | Age of onset          |              |             |                 | Age of onset      |              |            |                 |                     |           |           |                  |                   |              |            |         |
|------------------|-------------------|-------------------|--------------|-------------|-------------------|-------------------------|--------------|-------------|------------------|--------------------|--------------|------------|-----------------|-------------------------------|--------------|------------|------------------|-----------------------|--------------|-------------|-----------------|-------------------|--------------|------------|-----------------|---------------------|-----------|-----------|------------------|-------------------|--------------|------------|---------|
|                  |                   | Myopathy          |              |             |                   | Paget's Disease of Bone |              |             |                  | Dementia           |              |            |                 | Amyotrophic Lateral Sclerosis |              |            |                  | Peripheral Neuropathy |              |             |                 | Cardiomyopathy    |              |            |                 | Parkinson's Disease |           |           |                  | Cataracts         |              |            |         |
|                  |                   | N (%)             | Mean         | Range       | p-value           | N (%)                   | Mean (yrs)   | Range       | p-value          | N (%)              | Mean (yrs)   | Range      | p-              | N (%)                         | Mean         | Range      | p-               | N (%)                 | Mean (yrs)   | Range       | p-              | N (%)             | Mean         | Range      | p-              | N (%)               | Mean      | Range     | p-value          | N (%)             | Mean (yrs)   | Range      | p-value |
| p.Arg155His      | 18 (36.0%)        | 17 (45.9%)        | 40.6 ± 8.2   | 27-59       | 0.12              | 3 (25.0%)               | 41.3 ± 10.0  | 30-49       | 0.61             | 2 (40.0%)          | 43.5 ± 4.9   | 40-47      | 0.23            | 2 (100.0%)                    | 52.5 ± 9.2   | 46-59      | 1.0              | 4 (80.0%)             | 44.3 ± 13.1  | 27-59       | 0.99            | 1 (25.0%)         | 36.0         | 36         | NA              | 1 (100.0%)          | 46.00     | 46        | NA               | 3 (42.9%)         | 45.3 ± 11.9  | 37-59      | 0.78    |
| p.Arg155Cys      | 8 (16.0%)         | 4 (10.8%)         | 39.3 ± 10.7  | 30-54       | 0.52              | 1 (8.3%)                | 33.0         | 33          | NA               | 0 (0.0%)           | NA           | NA         | NA              | 0 (0.0%)                      | NA           | NA         | NA               | 0 (0.0%)              | NA           | NA          | NA              | 2 (50.0%)         | 49.0 ± 7.1   | 44-54      | 0.47            | 0 (0.0%)            | NA        | NA        | NA               | 0 (0.0%)          | NA           | NA         | NA      |
| p.Arg159His      | 5 (10.0%)         | 1 (2.7%)          | 51.0         | 51          | NA                | 0 (0.0%)                | NA           | NA          | NA               | 2 (40.0%)          | 63.5 ± 10.6  | 56-71      | 0.39            | 0 (0.0%)                      | NA           | NA         | NA               | 0 (0.0%)              | NA           | NA          | NA              | 0 (0.0%)          | NA           | NA         | NA              | 0 (0.0%)            | NA        | NA        | NA               | 0 (0.0%)          | NA           | NA         | NA      |
| p.Arg93Cys       | 4 (8.0%)          | 3 (8.1%)          | 52.3 ± 6.8   | 47-60       | 0.14              | 3 (25.0%)               | 52.7 ± 7.4   | 47-61       | 0.21             | 0 (0.0%)           | NA           | NA         | NA              | 0 (0.0%)                      | NA           | NA         | NA               | 0 (0.0%)              | NA           | NA          | NA              | 0 (0.0%)          | NA           | NA         | NA              | 0 (0.0%)            | NA        | NA        | NA               | 3 (42.9%)         | 49.7 ± 9.3   | 42-60      | 0.73    |
| p.Arg159Cys      | 4 (8.0%)          | 1 (2.7%)          | 50.0         | 50          | NA                | 0 (0.0%)                | NA           | NA          | NA               | 1 (20.0%)          | 50.0         | 50         | NA              | 0 (0.0%)                      | NA           | NA         | NA               | 0 (0.0%)              | NA           | NA          | NA              | 0 (0.0%)          | NA           | NA         | NA              | 0 (0.0%)            | NA        | NA        | NA               | 0 (0.0%)          | NA           | NA         | NA      |
| p.Arg191Gln      | 3 (6.0%)          | 3 (8.1%)          | 42.7 ± 4.6   | 40-48       | 0.89              | 0 (0.0%)                | NA           | NA          | NA               | 0 (0.0%)           | NA           | NA         | NA              | 0 (0.0%)                      | NA           | NA         | NA               | 1 (20.0%)             | NA           | NA          | NA              | 1 (25.0%)         | 40           | 40         | NA              | 0 (0.0%)            | NA        | NA        | NA               | 1 (14.3%)         | NA           | NA         | NA      |
| p.Leu198Trp      | 2 (4.0%)          | 2 (5.4%)          | 38.0         | 38          | NA                | 1 (8.3%)                | 38.0         | 38          | NA               | 0 (0.0%)           | NA           | NA         | NA              | 0 (0.0%)                      | NA           | NA         | NA               | 0 (0.0%)              | NA           | NA          | NA              | 0 (0.0%)          | NA           | NA         | NA              | 0 (0.0%)            | NA        | NA        | NA               | 0 (0.0%)          | NA           | NA         | NA      |
| p.Gly97Glu       | 1 (2.0%)          | 1 (2.7%)          | 47.0         | 47          | NA                | 1 (8.3%)                | 47.0         | 47          | NA               | 0 (0.0%)           | NA           | NA         | NA              | 0 (0.0%)                      | NA           | NA         | NA               | 0 (0.0%)              | NA           | NA          | NA              | 0 (0.0%)          | NA           | NA         | NA              | 0 (0.0%)            | NA        | NA        | NA               | 0 (0.0%)          | NA           | NA         | NA      |
| p.Ile369Thr      | 1 (2.0%)          | 1 (2.7%)          | 61.0         | 61          | NA                | 0 (0.0%)                | NA           | NA          | NA               | 0 (0.0%)           | NA           | NA         | NA              | 0 (0.0%)                      | NA           | NA         | NA               | 0 (0.0%)              | NA           | NA          | NA              | 0 (0.0%)          | NA           | NA         | NA              | 0 (0.0%)            | NA        | NA        | NA               | 0 (0.0%)          | NA           | NA         | NA      |
| p.Arg95Gly       | 1 (2.0%)          | 1 (2.7%)          | 40.0         | 40          | NA                | 1 (8.3%)                | 40.0         | 40          | NA               | 0 (0.0%)           | NA           | NA         | NA              | 0 (0.0%)                      | NA           | NA         | NA               | 0 (0.0%)              | NA           | NA          | NA              | 0 (0.0%)          | NA           | NA         | NA              | 0 (0.0%)            | NA        | NA        | NA               | 0 (0.0%)          | NA           | NA         | NA      |
| p.Asn387Thr      | 1 (2.0%)          | 1 (2.7%)          | 58.0         | 58          | NA                | 1 (8.3%)                | 58.0         | 58          | NA               | 0 (0.0%)           | NA           | NA         | NA              | 0 (0.0%)                      | NA           | NA         | NA               | 0 (0.0%)              | NA           | NA          | NA              | 0 (0.0%)          | NA           | NA         | NA              | 0 (0.0%)            | NA        | NA        | NA               | 0 (0.0%)          | NA           | NA         | NA      |
| p.Gly128Ala      | 1 (2.0%)          | 1 (2.7%)          | 40.0         | 40          | NA                | 1 (8.3%)                | 40.0         | 40          | NA               | 0 (0.0%)           | NA           | NA         | NA              | 0 (0.0%)                      | NA           | NA         | NA               | 0 (0.0%)              | NA           | NA          | NA              | 0 (0.0%)          | NA           | NA         | NA              | 0 (0.0%)            | NA        | NA        | NA               | 0 (0.0%)          | NA           | NA         | NA      |
| p.Gly782Ala      | 1 (2.0%)          | 1 (2.7%)          | 42.0         | 42          | NA                | 0 (0.0%)                | NA           | NA          | NA               | 0 (0.0%)           | NA           | NA         | NA              | 0 (0.0%)                      | NA           | NA         | NA               | 0 (0.0%)              | NA           | NA          | NA              | 0 (0.0%)          | NA           | NA         | NA              | 0 (0.0%)            | NA        | NA        | NA               | 0 (0.0%)          | NA           | NA         | NA      |
| <b>50 (100%)</b> | <b>37 (74.0%)</b> | <b>43.3 ± 8.8</b> | <b>27-60</b> | <b>0.87</b> | <b>12 (24.0%)</b> | <b>44.8 ± 9.3</b>       | <b>30-61</b> | <b>0.99</b> | <b>5 (10.0%)</b> | <b>52.8 ± 11.7</b> | <b>40-71</b> | <b>1.0</b> | <b>2 (4.0%)</b> | <b>52.5 ± 9.2</b>             | <b>46-59</b> | <b>1.0</b> | <b>5 (10.0%)</b> | <b>44.3 ± 13.1</b>    | <b>27-59</b> | <b>0.99</b> | <b>4 (8.0%)</b> | <b>43.5 ± 7.7</b> | <b>36-54</b> | <b>1.0</b> | <b>1 (2.0%)</b> | <b>46.00</b>        | <b>46</b> | <b>NA</b> | <b>7 (14.0%)</b> | <b>47.5 ± 9.8</b> | <b>37-60</b> | <b>1.0</b> |         |

Abbreviations: N number, ALS amyotrophic lateral sclerosis

NA indicates not applicable. No participants reported to have the corresponding symptoms in the phenotype categories.